{"id":"active-comparator-gardasil-9","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Injection site pain/soreness"},{"rate":"25–35","effect":"Injection site swelling"},{"rate":"20–30","effect":"Injection site erythema"},{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Fever"},{"rate":"5–10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3983509","moleculeType":"Small molecule","molecularWeight":"434.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GARDASIL 9 contains virus-like particles (VLPs) derived from nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against the targeted HPV types, preventing viral infection of epithelial cells and reducing the risk of HPV-related malignancies and genital warts. The vaccine provides protection against both low-risk HPV types (6, 11) that cause benign warts and high-risk types (16, 18, 31, 33, 45, 52, 58) associated with cervical, anal, and other cancers.","oneSentence":"GARDASIL 9 is a recombinant human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against nine HPV types to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:06.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of genital warts caused by HPV types 6, 11"},{"name":"Prevention of anal cancer and other HPV-related cancers"}]},"trialDetails":[{"nctId":"NCT04508309","phase":"PHASE3","title":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-15","conditions":"Cervical Cancer","enrollment":1025},{"nctId":"NCT05372016","phase":"PHASE3","title":"Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","status":"COMPLETED","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2020-09-19","conditions":"HPV Infections, Cervical Cancer, Vulvar Cancer","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active Comparator: GARDASIL ®9","genericName":"Active Comparator: GARDASIL ®9","companyName":"Shanghai Bovax Biotechnology Co., Ltd.","companyId":"shanghai-bovax-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"GARDASIL 9 is an active comparator in a clinical study evaluating its immunogenicity and safety in Chinese healthy females. The study is a randomized, double-blind, and positive-controlled Phase 3 study to evaluate the immunogenicity and safety of a 9-valent HPV recombinant vaccine in comparison to GARDASIL 9.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}